Scientist profiles G-L
Sunnybrook Research Institute
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room M7 434
Administrative Assistant: Kimberly Allen
- B.Sc., 1978, biochemistry specialization, Concordia University, Canada
- PhD, 1983, biochemistry, University of Alberta, Canada
- Postdoctoral fellow, 1986, medical microbiology, Stanford University, U.S.
Appointments and Affiliations:
- Senior scientist, Physical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
- SRI Research Chair in Biomolecular Engineering
- Professor, department of medical biophysics, University of Toronto
- Professor (cross-appointment), department of pharmaceutical sciences, University of Toronto
- Combinatorial libraries
- Peptide-based delivery vectors
- Tumour biology
- Toxin transport
The process of drug discovery needs to be accelerated if our society is to cope with rapidly rising numbers of cancer patients, newly unveiled mechanisms of drug resistance and the realization that cancer represents a collection of diseases that will require the tailoring of more selective therapies. Synthetic, combinatorial and genetic approaches are being applied in our laboratory to design peptide-oligonucleotide-based delivery shuttles or to re-engineer large structural templates such as bacterial toxins with the view to generating selective vehicles, imaging agents and therapies to treat cancer patients. The strategies developed in our laboratory will be applicable to other diseases.
See current publications list at PubMed.
- Ryan SO, Turner MS, Gariépy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 2010 Jul 15; 70(14):5788-96.
- Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):438-46.
- Orava EW, Cicmil N, Gariépy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta. 2010 Dec; 1798(12):2190-200.
- Cheung MC, Revers L, Perampalam S, Wei X, Kiarash R, Green DE, Abdul-Wahid A, Gariepy J. An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo. Mol Cancer. 2010 Feb 3; 9:28.
- Hassane FS, Ivanova GD, Bolewska-Pedyczak E, Abes R, Arzumanov AA, Gait MJ, Lebleu B, Gariépy J. A Peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem. 2009 Aug 19; 20(8):1523-1530.
- Ferreira CS, Cheung MC, Bisland S, Missailidis S, Gariepy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009 Feb; 37(3):866-76.
Related News and Stories:
- Tool kit: GE T200 surface plasmon resonance system: Scientist uses optical detection method to develop therapies and imaging tools for diseases (Sept. 26, 2013)
- Writing a PhD thesis: Getting it done and enjoying the process (July 5, 2013)
- Making the cut: Amid fiscal challenges, SRI researchers get funded (Feb. 7, 2013)
- Happy hour: SRI scientists talk cancer vaccines at café scientifique (June 27, 2012)
- Cancer researcher moves to Sunnybrook with sights set on novel therapies (May 4, 2010)
- Vaccine could delay bowel inflammation and colon cancer: An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of IBD and in turn prevent progression to colon cancer (ScienceDaily, March 25, 2010)
- Vaccine could delay bowel inflammation and colon cancer (HealthNewsDigest.com, March 24,2010)
- Researcher of the month: New skin cancer treatment may come from E. Coli (Canadian Cancer Society, June 2009)
- Merchant Scientists: How commercialization is changing research in Canada (Walrus Magazine, May 2008)